Bio-Pharma Ecosystems

In a post-blockbuster world, one-size-fits-all drug development and commercialization cannot succeed. Oliver Wyman believes that a much more nuanced approach is needed, one that recognizes the distinct characteristics of different submarkets—ecosystems—each with distinct dynamics, stakeholders, and economics. To operate effectively within these emerging ecosystems, companies need:

• Critical insight into the portfolio of current and future products, focusing on how it maps to the healthcare ecosystems, and how your business—from R&D to commercialization to distribution—must adapt to the unique requirements of each ecosystem.
• A pathway to the future based on an analysis of your current situation, likely market shifts, and the full range of strategies for migrating to an advantaged position in the new landscape.
• Short-term strategies to maximize access and profitability for new products that must clear a "higher bar" to compete and satisfy requirements for both clinical and economic impact that are emerging with value driven healthcare markets.